(a)This section applies to an office based
opioid treatment provider who:
(1)has obtained a waiver from the federal Substance Abuse and
Mental Health Services Administration (SAMHSA) and meets the
qualifying standards required to treat opioid addicted patients in
an office based setting; and
(2)has a valid federal Drug Enforcement Administration
registration number and identification number that specifically
authorizes treatment in an office based setting.
(b)The office of the secretary and the division shall develop a
treatment protocol containing best practice guidelines for the treatment
of opiate dependent patients. The treatment protocol must require the
minimal clinically necessary medication dose that includes, when
appropriate, the goal of opioid abstinence, and the following:
Free access — add to your briefcase to read the full text and ask questions with AI
(a) This section applies to an office based
opioid treatment provider who:
(1) has obtained a waiver from the federal Substance Abuse and
Mental Health Services Administration (SAMHSA) and meets the
qualifying standards required to treat opioid addicted patients in
an office based setting; and
(2) has a valid federal Drug Enforcement Administration
registration number and identification number that specifically
authorizes treatment in an office based setting.
(b) The office of the secretary and the division shall develop a
treatment protocol containing best practice guidelines for the treatment
of opiate dependent patients. The treatment protocol must require the
minimal clinically necessary medication dose that includes, when
appropriate, the goal of opioid abstinence, and the following:
(1) Require an opioid treatment provider to periodically and
randomly test a patient for the following before and during the
patient's treatment by the provider:
(A) Methadone.
(B) Cocaine.
(C) Opiates.
(D) Amphetamines.
(E) Barbiturates.
(F) Tetrahydrocannabinol.
(G) Benzodiazepines.
(H) Any other suspected or known drug that may have been
abused by the patient.
(2) Require that if a patient tests positive under a test described in
subdivision (1) for:
(A) a controlled substance other than a drug for which the
patient has a prescription or that is part of the patient's
treatment plan with the provider; or
(B) an illegal drug other than the drug that is part of the
patient's treatment plan with the provider;
the opioid treatment provider and the patient shall review the
treatment plan and consider changes with the goal of opioid
abstinence.
(3) Require that an opioid treatment provider must determine that
the benefit to the patient in receiving the take home opioid
treatment medication outweighs the potential risk of diversion of
the take home opioid treatment medication.
(4) Develop clinical standards for:
(A) the appropriate tapering of a patient on and off an opioid
treatment medication;
(B) relapse; and
(C) overdose prevention.
(5) Develop standards and protocols for an opioid treatment
provider to do the following:
(A) Assess new opioid treatment patients to determine the most
effective opioid treatment medications to start the patient's
opioid treatment.
(B) Ensure that each patient voluntarily chooses maintenance
treatment and that relevant facts concerning the use of opioid
treatment medications, including nonaddictive medication
options, are clearly and adequately explained to the patient.
(C) Have appropriate opioid treatment patients who are
receiving maintenance medications for opioid treatment move
to receiving other approved opioid treatment medications.
(c) Before December 31, 2016, the office of the secretary shall
recommend the best practice guidelines required under subsection (b)
to:
(1) the Indiana professional licensing agency established under IC 25-1-5;
(2) the office; and
(3) a managed care organization that has contracted with the
office.